Effectiveness of Niclosamide as Add-on Therapy to the Standard of Care Measures in COVID-19 Management

• Status: Recruiting
• Trial end date: 2021-12-03
• Target enrollment: 0
• Participant gender: All

Summary

Assessment of the Effectiveness of Niclosamide as Add on Therapy to the Standard of care Measures in COVID-19 Management in a randomized controlled clinical trial

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: University of Baghdad
• Treatments: Niclosamide

Criteria

Inclusion Criteria:

1. Patients with age above 18 years and of any gender.

2. Definite diagnosis of COVID-19 according to the WHO classification criteria ( 18).

3. Patients symptomatic for no more than three days for mild-moderate cases, no more than two days after being severe cases, and no more than one day after being critical cases.

4. Understands and agrees to comply with planned study procedures.

Exclusion Criteria:

1. Patients refuse to enrol in the study

2. Patients with hypersensitivity or severe adverse effects to niclosamide

3. Renal impairment

4. Hepatic impairment

5. Pregnancy or a desire to become pregnant

6. Breast feeding